EcoDrugPlus

Alpha Glucosidase

Ensembl ID : ENSCSEG00000015964
Gene Symbol: GAA
3 Cross references
233 Possible Orthologues:

Alpha-1a Adrenergic Receptor-Like

Ensembl ID : ENSCSEG00000016882
Gene Symbol: LOC103397722
3 Cross references
202 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSCSEG00000001650
Gene Symbol: LOC103389365
3 Cross references
156 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSCSEG00000019437
Gene Symbol: LOC103397793
3 Cross references
175 Possible Orthologues:

Alpha-Synuclein-Like

Ensembl ID : ENSCSEG00000019908
Gene Symbol: LOC103390286
2 Cross references
189 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSCSEG00000007486
Gene Symbol: AOC1
3 Cross references
233 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSCSEG00000013131
Gene Symbol: APP
4 Cross references
206 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSCSEG00000003260
Gene Symbol: LOC103391597
3 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSCSEG00000014074
Gene Symbol: AR
2 Cross references
214 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSCSEG00000018021
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:

Anti-Apoptotic Protein Nr13

Ensembl ID : ENSCSEG00000013079
Gene Symbol: LOC103379424
3 Cross references
129 Possible Orthologues:

Apelin Receptor 2

Ensembl ID : ENSCSEG00000009570
Gene Symbol: APLNR2
1 Cross references
172 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).